Why Need to Watch: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Galectin Therapeutics, Inc. (NASDAQ:GALT), Kyocera Corp. (NYSE:KYO), Biocept, Inc. (NASDAQ:BIOC), The Bancorp Inc. (NASDAQ:TBBK)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported a second-quarter 2015 loss of 10 cents per share, much narrower than the year-ago loss of 35 cents and the Zacks Consensus Estimate of a loss of 16 cents. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) belongs to Healthcare sector. Its weekly performance is -4.86%. On last trading day company shares ended up $1.37. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) distance from 50-day simple moving average (SMA50) is -23.06%.

On 3 August, Exalenz Bioscience announced it will collaborate with Galectin Therapeutics Inc. (NASDAQ:GALT) and use their noninvasive product, the BreathID test, for Galectin’s phase 2 clinical trial that will be investigating GR-MD-02 for the treatment of patients with nonalcoholic steatohepatitis with cirrhosis, according to a press release. Galectin Therapeutics, Inc. (NASDAQ:GALT) shares fell -14.35% in last trading session and ended the day at $1.97. GALT return on assets is -52.20%. Galectin Therapeutics, Inc. (NASDAQ:GALT) quarterly performance is -28.88%.

Kyocera Corp (NYSE:KYO) said last week its unit Kyocera Solar Inc is completing a 3.2-MW highway solar-lighting project in Brazil. Named Arco Metropolitano do Rio de Janeiro, the highway project is the largest in the country, connecting the five main highways crossing Rio de Janeiro state. On 11 August, Kyocera Corp. (NYSE:KYO) shares fell -1.08% and was closed at $51.31. KYO EPS growth in last 5 year was 23.60%. Kyocera Corp. (NYSE:KYO) year to date (YTD) performance is 11.98%.

Biocept Inc. (NASDAQ:BIOC) announced a collaboration with UC Irvine to evaluate biomarkers detected from blood-based versus invasive tissue biopsies in patients with metastatic cancers, and DexCom Inc. announced it has entered into an agreement with the life sciences team at Google to jointly develop a series of next-generation continuous glucose monitoring products that are designed to be smaller and less expensive than existing technologies, according to company announcements. Biocept, Inc. (NASDAQ:BIOC) ended the last trading day at $1.89. Company weekly volatility is calculated as 14.50% and price to cash ratio as 1.75. Biocept, Inc. (NASDAQ:BIOC) showed a weekly performance of -20.25%.

Zacks cut shares of Bancorp Inc. (NASDAQ:TBBK) from a buy rating to a hold rating in a research report sent to investors on Friday. The Bancorp Inc. (NASDAQ:TBBK) shares fell -1.57% in last trading session and ended the day at $8.15. TBBK return on assets is -0.40%. The Bancorp Inc. (NASDAQ:TBBK) quarterly performance is -17.34%.

Leave a Reply

Your email address will not be published. Required fields are marked *